Minerva Neurosciences

NERV53

Penny Stock

$2.14arrow_drop_down8.18%-$0.18

Penny Stock

NERV53

$2.14

arrow_drop_down8.18%-$0.18

Penny Stock

Performance History

Key Stats
Open	$2.28
Prev. Close	$2.32
EPS	-0.45
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$15.38M
PE Ratio	-

	LOW	HIGH
Day Range	2.11	2.36
52 Week Range	2.11	13.49

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.45

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Minerva Neurosciences (NERV)

Minerva Neurosciences Inc (NERV) is a pharmaceutical company that focuses on the development of innovative therapies for central nervous system (CNS) disorders. With a primary focus on schizophrenia, major depressive disorder (MDD), insomnia, and Parkinson's disease, Minerva Neurosciences aims to address unmet medical needs in these areas. The company's drug development pipeline includes several promising candidates that are currently in various stages of clinical trials. With a dedicated team of researchers and scientists, Minerva Neurosciences is committed to advancing the field of neuroscience and improving the lives of patients suffering from CNS disorders.

In terms of financials, Minerva Neurosciences has a market capitalization of $XXX million. The stock price of NERV has shown significant volatility over the past years, with a 52-week range of $XX to $XX. The day range for NERV stock is currently $XX to $XX. Trading volume for Minerva Neurosciences has been relatively high, indicating investor interest in the company. Despite the volatility, Minerva Neurosciences has shown resilience and continued to make progress in its drug development programs.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Remy Luthringer Ph.D.
Headquarters: Burlington
Employees: 9
Exchange: NASDAQ

Keep an eye on Minerva Neurosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Minerva Neurosciences 's (NERV) price per share?

The current price per share for Minerva Neurosciences (NERV) is $2.14. The stock has seen a price change of -$0.19 recently, indicating a -8.19% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Minerva Neurosciences (NERV)?

For Minerva Neurosciences (NERV), the 52-week high is $13.49, which is 530.37% from the current price. The 52-week low is $2.11, the current price is 1.37% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Minerva Neurosciences (NERV) a growth stock?

Minerva Neurosciences (NERV) has shown an average price growth of -6.65% over the past three years. It has received a score of 17 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Minerva Neurosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Minerva Neurosciences (NERV) stock price performance year to date (YTD)?

As of the latest data, Minerva Neurosciences (NERV) has a year-to-date price change of -65.2%. Over the past month, the stock has experienced a price change of -19.85%. Over the last three months, the change has been -16.08%. Over the past six months, the figure is -16.69%. Looking at a longer horizon, the five-year price change stands at -94.78%.

help

Is Minerva Neurosciences (NERV) a profitable company?

Minerva Neurosciences (NERV) has a net income of -$30.01M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$23.12M. Furthermore, the EBITDA is -$24.49M.

help

What is the market capitalization of Minerva Neurosciences (NERV)?

Minerva Neurosciences (NERV) has a market capitalization of $15.39M. The average daily trading volume is 2.21, indicating the stock's liquidity and investor engagement.